Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-04-14, Stock:LLY, The news for the past five days is as follows:
2021-04-07: NEWS1: Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed.
2021-04-08: NEWS1: Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal.NEWS2: Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal.NEWS3: Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients.
2021-04-09: NEWS1: Top Stock Reports for Oracle, Eli Lilly & BP.NEWS2: Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study.NEWS3: Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes.NEWS4: NIH recommends Lilly and Regeneron's combination antibody treatments to people with mild and moderate COVID-19.NEWS5: Provention Bio Shares Crash 40% Due To Regulatory Setback For Diabetes Drug.NEWS6: Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes.
2021-04-12: NEWS1: COVID-19 cases keep surging in some U.S. states, and Michigan governor continues plea for more vaccines as shots in arms hits daily record.NEWS2: Lilly says U.S. government modified purchases of its COVID-19 antibody treatments.NEWS3: The Zacks Analyst Blog Highlights: Oracle, Eli Lilly and BP.NEWS4: UPDATE 1-Eli Lilly to focus on selling COVID-19 antibody drug combination.NEWS5: Eli Lilly ends supply agreement with U.S. govt for COVID-19 antibody drug.NEWS6: Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together.
2021-04-13: NEWS1: Longeveron: A High-Quality Emerging Biotech Play.NEWS2: Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer.

Answer: Rise